AI Article Synopsis

  • Anti-retroviral therapy significantly reduces viral load and increases CD4+ cell counts in HIV-infected patients, as shown in a study with six untreated individuals who began treatment with Zidovudine and Didanosine.
  • The study observed notable changes in CD4+ cell types within the first 14 days, including an increased ratio of CD4+CD45RA+ to CD4+CD45RO+ cells and decreased expression of CD95/Fas.
  • Newly generated CD4+ cells were found to be mostly CD45RA+ and CD95/Fas-, indicating a potential early population of naïve cells that are not yet primed for apoptosis, with a conserved T cell receptor repertoire for effective immune response.

Article Abstract

Administration of anti-retroviral drugs induces a decrease of viral load associated with increase of CD4+ cell count in most HIV-infected patients. To investigate the early changes in CD4+ cell phenotype induced by anti-retroviral therapy, six patients with CD4+ cell count > 100/mm3 and never treated with anti-HIV therapy were enrolled and blood samples collected several times within 14 days from the initiation of therapy with Zidovudine plus Didanosine. CD4+ cell count and HIV viraemia were investigated at each time point, as well as the expression of CD45RA, CD45RO and CD95/Fas molecules on CD4+ cells, and the T cell receptor (TCR) Vbeta repertoire of CD4+ cells. All patients showed a rapid and dramatic decrease in viral load with a corresponding increase of CD4+ cell count. The main remodelling of CD4+ cell subpopulations took place in the first 14 days of therapy, and consisted of: (i) increased CD4+CD45RA+/CD4+CD45RO+ ratio; (ii) decrease of CD95/Fas expression. The rise in absolute number of CD4+CD45RA+ cells was paralleled by an increase of CD4+CD95/Fas- cells and accounted for most of the early increment of CD4+ cell count. The TCR Vbeta repertoire of CD4+ cells was conserved after anti-HIV therapy, with the exception of two patients with expanded CD4+Vbeta12+ cells, which also tested CD45RA+ and CD95/Fas-. These experiments show that newcomer CD4+ lymphocytes are CD45RA+CD95/Fas- cells, suggesting that blocking HIV replication causes an early and antigen-independent proliferation of possibly 'naive' cells unprimed for CD95/Fas-mediated apoptosis. These cells expressed a conserved and widespread TCR repertoire, suggesting that their capability for antigenic recognition is intact.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904844PMC
http://dx.doi.org/10.1046/j.1365-2249.1998.00464.xDOI Listing

Publication Analysis

Top Keywords

cd4+ cell
28
cell count
20
cd4+
13
increase cd4+
12
cd4+ cells
12
cells
10
cells conserved
8
induced anti-retroviral
8
anti-retroviral therapy
8
hiv-infected patients
8

Similar Publications

Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines.

Hum Vaccin Immunother

December 2025

TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

The dissemination of tumor cells with ensuing metastasis is responsible for most cancer-related deaths. Cancer vaccines may, by inducing tumor-specific effector T cells, offer a strategy to eliminate metastasizing tumor cells. However, several obstacles remain in the development of effective cancer vaccines, including the identification of adjuvants that enhance the evolvement and efficacy of tumor-specific T cells.

View Article and Find Full Text PDF

Background And Aims: To estimate the biological variation (BV) for lymphocyte subset counts in healthy adults based on full-spectrum flow cytometry (FS-FCM) and the most commonly used BD Multitest 6-Color TBNK kit in China.

Materials And Methods: The study was designed according to the BV Data Critical Appraisal Checklist (BIVAC). Peripheral blood samples were collected from 60 healthy adults every two weeks for a period of 20 weeks (10 samples from each subject).

View Article and Find Full Text PDF

Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events.

Eur J Cancer

January 2025

Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany; Experimental and Clinical Research Center, A Cooperation of Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany. Electronic address:

Background: Despite remarkable clinical efficacy, little is known about the system-wide immunological alterations provoked by PD1 blockade. Dynamics of quantitative immune composition and functional repertoire during PD1 blockade could delineate cohort-specific patterns of treatment response and therapy-induced toxicity.

Methods: We longitudinally assessed therapy-induced effects on the immune system in fresh whole blood using flow cytometry-based cell quantifications, accompanied by analyses of effector properties of all major immune populations upon cell-type specific stimulations.

View Article and Find Full Text PDF

Schizophrenia and retention in HIV care among adults insured through Medicaid in the United States: a population-based retrospective cohort study.

J Acquir Immune Defic Syndr

January 2025

Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California-San Francisco, School of Medicine, San Francisco, California 675 18th Street, San Francisco, CA 94107.

Background: People with schizophrenia spectrum disorders are at elevated risk of HIV, and people with both HIV and schizophrenia are at elevated risk of death compared to individuals with either diagnosis alone. Limited research has assessed the HIV care cascade, and in particular retention in care, among people with HIV (PWH) and schizophrenia in the U.S.

View Article and Find Full Text PDF

CD8+ T cells are critical for immune protection against severe COVID-19 during acute infection with SARS-CoV-2. However, the induction of antiviral CD8+ T cell responses varies substantially among infected people, and a better understanding of the mechanisms that underlie such immune heterogeneity is required for pandemic preparedness and risk stratification. In this study, we analyzed SARS-CoV-2-specific CD4+ and CD8+ T cell responses in relation to age, clinical status, and inflammation among patients infected primarily during the initial wave of the pandemic in France or Japan.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!